6567-35-7

Basic information

• Product Name: 3-BROMOISOXAZOLE-5-CARBOXYLIC ACID
• Synonyms: 3-BROMOISOXAZOLE-5-CARBOXYLIC ACID;3-BROMOISOXAZOLE-5-CARBOXYLIC ACID, 95+%;3-Bromo-5-carboxyisoxazole, 3-Bromo-1,2-oxazole-5-carboxylic acid, 3-Bromo-5-carboxy-1,2-oxazole;3-broMoisothiazole-5-carboxylic acid;3-BroMo-5-carboxyisoxazole;3-broMo-1,2-oxazole-5-carboxylic acid;3-Bromo-5-isoxazolecarboxylic acid
• CAS NO: 6567-35-7
• Molecular Formula: C₄H₂BrNO₃
• Molecular Weight: 191.97
• EINECS: 200-158-5
• Product Categories: Isoxazole series;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles;Carboxylic Acids;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 6567-35-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 170-175 °C
• Boiling Point: 375.162 °C at 760 mmHg
• Flash Point: 180.692 °C
• Appearance: /
• Density: 2.039 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 1.90±0.10(Predicted)
• CAS DataBase Reference: 3-BROMOISOXAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOISOXAZOLE-5-CARBOXYLIC ACID(6567-35-7)
• EPA Substance Registry System: 3-BROMOISOXAZOLE-5-CARBOXYLIC ACID(6567-35-7)

Safety Data

• Hazardous Substances Data: 6567-35-7(Hazardous Substances Data)

Usage

Uses

3-Bromoisoxazole-5-carboxylic Acid has been used for the preparation of oxazolidinone with substituted isoxazole derivatives to be used as antibacterial agents.

InChI:InChI=1/C4H2BrNO3/c5-3-1-2(4(7)8)9-6-3/h1H,(H,7,8)

Upstream product

• 25742-00-1 (3-bromoisoxazol-5-yl)methanol 
• 105174-97-8 3-Bromo-5-isoxazolecarboxylic Acid Ethyl Ester 
• 1392517-50-8 3-bromo-4,5-dihydro-5-tert-butoxyformylisoxazole 
• 272773-11-2 methyl 3-bromoisoxazole-5-carboxylate 

Downstream Products

• 13626-59-0 3-methoxyisoxazole-5-carboxylic acid 
• 2552-54-7 3-(benzyloxy)isoxazole-5-carboxylic acid 
• 76596-53-7 3-bromo-5-acetyl-isoxazole 
• 1392517-51-9 2-(3-bromoisoxazol-5-yl)-5-(2-trifluoromethylphenyl)-1H-benzimidazole 

Relevant articles and documents

Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro

The discovery and development of a novel HER-2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer are presented in this article. EGFR family has been recognized as a crucial meditator in the cancer progression; HER-2 tyrosine kinase was one of the members among them. In the effort to explore potent HER-2 inhibitors, a novel series of 4-anilino-3-cyanoquinoline derivatives have been designed, synthesized and evaluated. Most compounds possessed modest proliferation inhibition on SK-BR-3 cell line and HER-2 kinase. Compound 16 appeared to be the most potent compound (HER-2 kinase IC50: 19.4?nM, SK-BR-3 IC50: 94?nM). In the experiment of cellular cytotoxicity assay, compound 16 shows a much lower cytotoxicity than neratinib on Beas-2b cell line (Human bronchial epithelial cells). In conclusion, compound 16 would be a promising lead compound for further anti-breast cancer drug discovery.

Structure-activity studies of 6-substituted decahydroisoquinoline-3- carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity

We have explored the excitatory amino acid antagonist activity in a series of decahydroisoquinoline-3-carboxyic acids, and within this series found the potent and selective AMPA antagonist (3SR,4aRS,6RS,8aRS)-6-(2-(1H-tetrazol- 5-yl)ethyl)decahydroisoquin